Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Sells $1,612,500.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 10,750 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $150.00, for a total value of $1,612,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Bruce C. Cozadd also recently made the following trade(s):

  • On Tuesday, October 1st, Bruce C. Cozadd sold 500 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $130.00, for a total value of $65,000.00.

JAZZ stock traded up $1.71 during mid-day trading on Wednesday, hitting $148.16. The company had a trading volume of 581,565 shares, compared to its average volume of 559,257. The company has a market capitalization of $8.38 billion, a price-to-earnings ratio of 12.10, a P/E/G ratio of 1.18 and a beta of 1.15. Jazz Pharmaceuticals PLC has a 12-month low of $113.52 and a 12-month high of $153.03. The company has a quick ratio of 3.71, a current ratio of 3.89 and a debt-to-equity ratio of 0.56. The company has a 50-day moving average price of $132.98 and a 200 day moving average price of $132.88.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 EPS for the quarter, topping the consensus estimate of $3.19 by $0.91. The business had revenue of $537.70 million for the quarter, compared to analysts’ expectations of $523.92 million. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 27.99%. The business’s quarterly revenue was up 14.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.58 EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 14.15 EPS for the current year.

Several equities analysts have recently issued reports on JAZZ shares. Piper Jaffray Companies lowered Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $205.00 to $142.00 in a report on Wednesday, August 21st. ValuEngine upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. TheStreet upgraded Jazz Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Friday, November 29th. Wells Fargo & Co raised their price target on Jazz Pharmaceuticals from $168.00 to $186.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $150.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, October 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $168.71.

Several hedge funds and other institutional investors have recently made changes to their positions in JAZZ. Commonwealth Equity Services LLC raised its position in shares of Jazz Pharmaceuticals by 2.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 3,338 shares of the specialty pharmaceutical company’s stock valued at $475,000 after buying an additional 92 shares in the last quarter. FDx Advisors Inc. raised its position in shares of Jazz Pharmaceuticals by 13.9% during the 2nd quarter. FDx Advisors Inc. now owns 1,657 shares of the specialty pharmaceutical company’s stock valued at $236,000 after buying an additional 202 shares in the last quarter. Rothschild & Co. Asset Management US Inc. raised its position in shares of Jazz Pharmaceuticals by 75.7% during the 2nd quarter. Rothschild & Co. Asset Management US Inc. now owns 228,543 shares of the specialty pharmaceutical company’s stock valued at $32,581,000 after buying an additional 98,491 shares in the last quarter. Bowling Portfolio Management LLC raised its position in shares of Jazz Pharmaceuticals by 190.7% during the 2nd quarter. Bowling Portfolio Management LLC now owns 41,244 shares of the specialty pharmaceutical company’s stock valued at $5,880,000 after buying an additional 27,055 shares in the last quarter. Finally, Virginia Retirement Systems ET AL raised its position in shares of Jazz Pharmaceuticals by 21.1% during the 2nd quarter. Virginia Retirement Systems ET AL now owns 141,600 shares of the specialty pharmaceutical company’s stock valued at $20,186,000 after buying an additional 24,700 shares in the last quarter. Hedge funds and other institutional investors own 89.10% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: Stock Symbols, CUSIP and Other Stock Identifiers

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.